Shire's rare-disease portfolio supports a narrow moat, despite the firm's reliance on acquisitions.
We continue to see Shire as significantly undervalued following 2017 financial results that beat our expectations. We’re maintaining our $205 per ADS fair value estimate (and slightly lowering our fair value estimate to GBX 4,890 per share) as we incorporate foreign exchange fluctuations as well as a slightly lower-than-expected 2018 earnings forecast from management. Overall, the firm’s immunology franchise continues to expand at a double-digit rate as uptake of subcutaneous products remains st...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.